^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lutetium-177 Octreotate (PNT2003)

    i
    Other names: PNT2003
    Associations

    News

    Trials
    Company:
    Eli Lilly, Lantheus
    Drug class:
    Ionizing radiation emitter, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (clinicaltrials.gov)
    P=N/A, N=195, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CHGA (Chromogranin A)
    |
    lutetium-177 Octreotate (PNT2003)
    2years
    The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. (PubMed, Nucl Med Commun)
    In patients with SSTR-RADS 5 PM-NETs treated with 177Lu-DOTATATE, there was similar response to therapy for all lesions with PET-generated Krenning score ≥2. No correlation was found between lesion's POD and level of tracer uptake.
    Clinical • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 expression • SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • lutetium-177 Octreotate (PNT2003)